Congratulations: Beilu Pharma's Iodixanol Injection Passed the Consistency Evaluation for Generic Drugs

Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA) on Iodixanol Injection (100ml:32g), and the company's visipaque package insert Injection passed the quality and efficacy consistency evaluation for generic drugs！It is the second contrast product of Belu passed the quality and efficacy consistency evaluation.

According to relevant national policies, appropriate support will be given to medical insurance payment for drug varieties that have passed the quality and consistency evaluation, and medical institutions will give priority to purchase and use in clinical practice. According to the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases" (Development and Reform Commission of the Office of the State Council [2021] No. 2), if the number of generic drugs that have passed the quality and consistency evaluation of online drugs exceeds 3, under the premise of ensuring supply, products that have not passed the quality and consistency evaluation will no longer be selected for centralized procurement.

The company's iohexol contrast passed the quality and consistency evaluation of generic drugs, which is conducive to enhancing the market competitiveness of the drugs, and at the same time, it has accumulated valuable experience for the company's subsequent development of the quality and consistency evaluation of generic drugs.